Abstract： Objective： To observe the clinical efficacy of modified Sanzi Yangqin Decoction combined with Tiotropium Bromide in the treatment of chronic obstructive pulmonary disease（COPD）and its impact on airway mucus hypersecretion. Methods： A total of 80 COPD patients admitted to Lishui People's Hospital from January 2022 to January 2024 were selected and divided into the Tiotropium Bromide group and the combined group using the random number table method，with 40 cases in each group. The Tiotropium Bromide group received Tiotropium Bromide Powder inhalation therapy on the basis of conventional western medicine treatment，while the combined group received modified Sanzi Yangqin Decoction in addition to the treatment of the Tiotropium Bromide group. Both groups were treated for two weeks. The clinical efficacy，changes in traditional Chinese medicine syndrome scores，lung function [forced expiratory volume in the first second（FEV1），maximum voluntary ventilation（MVV），and forced vital capacity（FVC）]，airway mucus hypersecretion [mucin5AC（MUC5AC）]，and inflammatory indicators [neutrophil（NEU），procalcitonin（PCT）， and C-reactive protein（CRP）] were compared before and after treatment between the two groups. Results： After treatment， the total effective rate was 95.00%（38/40）in the combined group and 80.00%（32/40）in the Tiotropium Bromide group， with a statistically significant difference between the two groups（P＜0.05）. After treatment， the traditional Chinese medicine syndrome scores in both groups were decreased compared with those before treatment（P＜ 0.05），and the scores in the combined group were lower than those in the Tiotropium Bromide group（P＜0.05）. After treatment，the levels of FEV1，FVC，and MVV in both groups were increased compared with those before treatment （P＜0.05）， and the levels of these three indicators in the combined group were higher than those in the Tiotropium Bromide group（P＜0.05）. After treatment，the levels of MUC5AC in both groups were decreased compared with those before treatment（P＜0.05）， and the levels in the combined group were lower than those in the Tiotropium Bromide group（P＜0.05）. After treatment，the levels of NEU，PCT，and CRP in both groups were decreased compared with those before treatment（P＜0.05），and the levels of these three indicators in the combined group were lower than those in the Tiotropium Bromide group（P＜0.05）. No severe adverse reactions were observed in either group during the treatment period. Conclusion：Modified Sanzi Yangqin Decoction combined with Tiotropium Bromide in the treatment of COPD can promote the improvement of lung function and traditional Chinese medicine syndrome， reduce inflammatory reactions，alleviate airway mucus hypersecretion，and improve clinical efficacy.